MILOTA, Tomas, Marta SOBOTKOVA, Jitka SMETANOVA, Marketa BLOOMFIELD, Jana VYDLAKOVA, Zita CHOVANCOVÁ, Jiří LITZMAN, Roman HAKL, Jiri NOVAK, Ivana MALKUSOVA, Jana HANZLIKOVA, Dalibor JILEK, Beata HUTYROVA, Vitezslav NOVAK, Irena KRCMOVA, Anna SEDIVA a Pavlina KRALICKOVA. Risk Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity-Results From a Multicenter Nationwide Study. Frontiers in Immunology. Laussane: Frontiers, 2022, roč. 13, February 2022, s. 1-8. ISSN 1664-3224. Dostupné z: https://dx.doi.org/10.3389/fimmu.2022.835770.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Risk Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity-Results From a Multicenter Nationwide Study
Autoři MILOTA, Tomas (203 Česká republika, garant), Marta SOBOTKOVA (203 Česká republika), Jitka SMETANOVA (203 Česká republika), Marketa BLOOMFIELD (203 Česká republika), Jana VYDLAKOVA (203 Česká republika), Zita CHOVANCOVÁ (203 Česká republika, domácí), Jiří LITZMAN (203 Česká republika, domácí), Roman HAKL (203 Česká republika, domácí), Jiri NOVAK (203 Česká republika), Ivana MALKUSOVA (203 Česká republika), Jana HANZLIKOVA (203 Česká republika), Dalibor JILEK (203 Česká republika), Beata HUTYROVA (203 Česká republika), Vitezslav NOVAK (203 Česká republika), Irena KRCMOVA (203 Česká republika), Anna SEDIVA (203 Česká republika) a Pavlina KRALICKOVA (203 Česká republika).
Vydání Frontiers in Immunology, Laussane, Frontiers, 2022, 1664-3224.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30102 Immunology
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 7.300
Kód RIV RIV/00216224:14110/22:00125669
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3389/fimmu.2022.835770
UT WoS 000769691000001
Klíčová slova anglicky COVID-19; SARS-CoV-2; hospital admission; inborn errors of immunity; mortality; risk factors
Štítky 14110114, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 14. 4. 2022 12:33.
Anotace
Despite the progress in the understanding how COVID-19 infection may impact immunocompromised patients, the data on inborn errors of immunity (IEI) remain limited and ambiguous. Therefore, we examined the risk of severe infection course and hospital admission in a large cohort of patients with IEI. In this multicenter nationwide retrospective survey-based trial, the demographic, clinical, and laboratory data were collected by investigating physicians from 8 national referral centers for the diagnosis and treatment of IEI using a COVID-19-IEI clinical questionnaire. In total, 81 patients with IEI (including 16 with hereditary angioedema, HAE) and confirmed SARS-CoV-2 infection were enrolled, and were found to have a 2.3-times increased (95%CI: 1.44-3.53) risk ratio for hospital admission and a higher mortality ratio (2.4% vs. 1.7% in the general population). COVID-19 severity was associated with the presence of clinically relevant comorbidities, lymphopenia, and hypogammaglobulinemia, but not with age or BMI. No individuals with HAE developed severe disease, despite a hypothesized increased risk due to perturbed bradykinin metabolism. We also demonstrated a high seroconversion rate in antibody-deficient patients and the safety of anti-spike SARS CoV-2 monoclonal antibodies and convalescent plasma. Thus, IEI except for HAE, represent significant risk factors for a severe COVID-19. Therefore, apart from general risk factors, immune system dysregulation may also be involved in the poor outcomes of COVID-19. Despite the study limitations, our results support the findings from previously published trials.
VytisknoutZobrazeno: 25. 4. 2024 08:14